Hepatocellular Carcinoma News and Research

RSS

Hepatocellular Carcinoma is a type of adenocarcinoma, the most common type of liver tumor.

Study suggests new strategies for using cell metabolism to treat cancer

Researchers at the University of Cincinnati College of Medicine have discovered that cell metabolism plays an important role in the ability of cells to start a survival program called autophagy, an unwanted side effect of some anti-cancer drugs that helps some tumor cells dodge treatment and eventually regrow into new tumors.

29 Aug 2018

Eisai: EC approves marketing of LENVIMA as first-line treatment for hepatocellular carcinoma

Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth N.J., U.S.A., known as MSD outside of the United States and Canada, announced today that the European Commission has granted a marketing authorization for the oral receptor tyrosine kinase inhibitor LENVIMA (lenvatinib mesylate) as a single agent for the first-line treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have received no prior systemic therapy.

23 Aug 2018

New drug delivery system delivers anticancer drugs that reduce tumor size

Cancer tissue cells are divided into two major groups: cancer cells and cancer stem cells. CSCs are related to cancer progression and dissemination, so it's necessary to eradicate CSCs in order to cure cancer.

9 Aug 2018

Scientists develop novel peptide drug that could potentially stop development of liver cancer

A research team led by scientists from the Cancer Institute of Singapore at the National University of Singapore has developed a novel peptide drug called FFW that could potentially stop the development of hepatocellular carcinoma or primary liver cancer.

2 Aug 2018

Alcohol-related cirrhosis mortality on the rise among young adults

Deaths from cirrhosis rose in all but one state between 1999-2016, with increases seen most often among young adults, a new study shows.

19 Jul 2018

Can-Fite BioPharma receives Australian and Chinese patents for new drug to treat erectile dysfunction

Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address liver diseases, inflammatory diseases and sexual dysfunction, today announced that the Australian and Chinese patent offices have granted the Company a patent for the utilization of A3 adenosine receptor ligands in the treatment of sexual dysfunction, in a patent (Australian, No. 2013301125ZL, Chinese No. 2013800472970) titled, "A3 adenosine receptor ligands for use in treatment of a sexual dysfunction."

17 Jul 2018

U.S. researchers recommend development of anti-cancer drugs based on mechanism of Namodenoson

Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced that U.S. researchers published scientific findings recommending development of anti-Liver Cancer Drugs based on a mechanism of action utilized by Namodenoson.

2 Jul 2018

Streamlining and translating basic science discoveries into the clinic

To make sure that good ideas to enhance healthcare are not lost due to a lack of resources, a growing number of centers at Penn Medicine organize forums to pitch ideas to improve medical devices and technology, hold annual competitions to fund studies to improve patient care while keeping costs down, and sponsor seed grants for programs focused on patients who need individualized tailoring of their treatment.

2 Jul 2018

Can-Fite provides update on Phase II clinical trial with drug candidate Namodenoson

Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today provided an update on its Phase II clinical trial with drug candidate Namodenoson in the treatment of advanced hepatocellular carcinoma in patients whose disease has progressed on sorafenib therapy.

19 Jun 2018

MiNA Therapeutics announces initial results from phase I trial of saRNA candidate in liver cancer patients

MiNA Therapeutics, the pioneer in RNA activation therapeutics, today announced preliminary results from its ongoing Phase I study of small activating RNA candidate MTL-CEBPA in advanced liver cancer.

4 Jun 2018

Scientists reveal role of lung scavenger cells in liver cancer spread to the lungs

Hepatocellular carcinoma is the most common form of liver cancer, and the third biggest cause of death from cancer worldwide.

4 Jun 2018

Opdivo plus low-dose Yervoy shows promising results in treating renal cell carcinoma patients

Bristol-Myers Squibb Company today announced patient-reported outcomes data from the Phase 3 CheckMate -214 trial in intermediate- and poor-risk patients with advanced renal cell carcinoma treated with the Immuno-Oncology combination Opdivo plus low-dose Yervoy versus sunitinib over a two-year follow-up period.

1 Jun 2018

Study: HCV-exposed infants not adequately screened, despite increased prevalence

Due to the opioid epidemic, hepatitis C virus is increasing among pregnant women, resulting in a greater risk of perinatal transmission and HCV infection among children.

2 May 2018

Study reports decreasing rates of liver transplantation among HCC patients in the U.S.

Patients with hepatocellular carcinoma (HCC) waiting for a liver transplant in the USA are now significantly less likely to receive a new liver than they were around a decade ago. A nationwide study presented today at The International Liver Congress™ 2018 in Paris, France, has confirmed that patients with HCC on the liver transplant list in the USA were more than 50% less likely to receive a transplant in 2014-2016 than they were in 2005-2007.

13 Apr 2018

OCA treatment stabilizes or reverses fibrosis/cirrhosis in patients with primary biliary cholangitis

The first results from the POISE biopsy sub-study have today confirmed that long-term treatment with obeticholic acid leads to the reversal or stabilization of fibrosis/cirrhosis in patients with primary biliary cholangitis who have had an incomplete response to ursodeoxycholic acid.

13 Apr 2018

Study confirms no survival benefit of adding SIRT to standard treatment for liver cancer

The final results of the palliative cohort of the SORAMIC study in patients with unresectable, locally advanced primary liver cancer have confirmed no clinical advantage to adding selective internal radiation therapy to standard sorafenib treatment compared with using sorafenib alone.

13 Apr 2018

New, sensitive HBV assay may allow earlier detection of hepatocellular carcinoma

Chronic hepatitis B virus (HBV) can progress to cirrhosis and hepatocellular carcinoma (HCC). A study published in The Journal of Molecular Diagnostics describes a new HBV assay that offers advantages over currently used methods because it has the capability to detect closed circular DNA (cccDNA) in serum, single cells, and preserved tissue samples.

12 Apr 2018

Study offers new hope for patients with intrahepatic cholangiocarcinoma

Kandice Fogle, 43, had just moved to Houston when she began experiencing pain in her back and groin. After undergoing a CT scan, doctors found a large mass in her liver. A biopsy confirmed that she had intrahepatic cholangiocarcinoma, more commonly known as bile duct cancer.

11 Apr 2018

Salk scientists discover protein that 'turns off' uncontrolled liver cancer growth

Salk Institute scientists, together with researchers from Switzerland's University of Basel and University Hospital Basel, discovered a protein called LHPP that acts as a molecular switch to turn off the uncontrolled growth of cells in liver cancer.

29 Mar 2018

Alcohol-related liver cancer may have poor prognosis than other types

A new study indicates that patients with alcohol-related liver cancer often do not live as long as patients with liver cancer that is not associated with alcohol consumption, mainly due to diagnoses at later stages.

28 Mar 2018

Hepatocellular Carcinoma News and Research

Further Reading

Study suggests new strategies for using cell metabolism to treat cancer

Eisai: EC approves marketing of LENVIMA as first-line treatment for hepatocellular carcinoma

New drug delivery system delivers anticancer drugs that reduce tumor size

Scientists develop novel peptide drug that could potentially stop development of liver cancer

Alcohol-related cirrhosis mortality on the rise among young adults

Can-Fite BioPharma receives Australian and Chinese patents for new drug to treat erectile dysfunction

U.S. researchers recommend development of anti-cancer drugs based on mechanism of Namodenoson

Streamlining and translating basic science discoveries into the clinic

Can-Fite provides update on Phase II clinical trial with drug candidate Namodenoson

MiNA Therapeutics announces initial results from phase I trial of saRNA candidate in liver cancer patients

Scientists reveal role of lung scavenger cells in liver cancer spread to the lungs

Opdivo plus low-dose Yervoy shows promising results in treating renal cell carcinoma patients

Study: HCV-exposed infants not adequately screened, despite increased prevalence

Study reports decreasing rates of liver transplantation among HCC patients in the U.S.

OCA treatment stabilizes or reverses fibrosis/cirrhosis in patients with primary biliary cholangitis

Study confirms no survival benefit of adding SIRT to standard treatment for liver cancer

New, sensitive HBV assay may allow earlier detection of hepatocellular carcinoma

Study offers new hope for patients with intrahepatic cholangiocarcinoma

Salk scientists discover protein that 'turns off' uncontrolled liver cancer growth

Alcohol-related liver cancer may have poor prognosis than other types

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News